Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs ...

It requires only light weights ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The former Superwoman is returning to sketch comedy, familiar characters, and the platform that made her famous.

Comedian Lilly Singh's network talk show fizzled out. Now she explains why she's returning to YouTube.

A new weight-loss drug from Eli Lilly (LLY +2.83%) may reset the bar for treating obesity and helping adults with type 2 diabetes lower their blood sugar. The company recently released information ...

Eli Lilly was second to market with a GLP-1 drug, but it quickly became the industry leader. The company recognizes that patents will only protect its GLP-1 drugs for just so long. The company, like ...

Eli Lilly is putting more of its metabolic medicines revenue to work, paying $100 million to begin a multi-drug research collaboration with Beijing-based InnoCare Pharma. Specific diseases and drug ...

Eli Lilly said its experimental combination regimen resulted in greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type ...

Eli Lilly recently stopped its development of a new GLP-1 weight-loss drug. The company had expectations for the drug's efficacy, and it didn't live up to them. It's unfortunate, but it happens.

HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli ‌Lilly worth ...